Annexon (NASDAQ:ANNX - Get Free Report) is projected to post its quarterly earnings results before the market opens on Tuesday, March 25th. Analysts expect Annexon to post earnings of ($0.28) per share for the quarter.
Annexon (NASDAQ:ANNX - Get Free Report) last announced its quarterly earnings data on Monday, March 3rd. The company reported ($0.33) earnings per share for the quarter, missing analysts' consensus estimates of ($0.28) by ($0.05). On average, analysts expect Annexon to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.
Annexon Stock Down 3.4 %
Annexon stock traded down $0.09 during mid-day trading on Friday, reaching $2.41. 1,289,318 shares of the company's stock were exchanged, compared to its average volume of 1,781,113. Annexon has a twelve month low of $2.30 and a twelve month high of $8.40. The company has a market cap of $263.85 million, a P/E ratio of -2.29 and a beta of 1.14. The company has a fifty day moving average of $3.30 and a 200-day moving average of $5.13.
Wall Street Analysts Forecast Growth
Several analysts have recently issued reports on ANNX shares. Needham & Company LLC reiterated a "buy" rating and issued a $16.00 price objective on shares of Annexon in a research note on Tuesday, March 4th. HC Wainwright reaffirmed a "buy" rating and issued a $30.00 price target on shares of Annexon in a research report on Tuesday, December 17th. Six equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, the company presently has a consensus rating of "Buy" and a consensus price target of $15.80.
Read Our Latest Stock Report on Annexon
About Annexon
(
Get Free Report)
Annexon, Inc, a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. Its lead candidate is ANX005, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase II clinical trial for the treatment of amyotrophic lateral sclerosis.
Featured Stories
Before you consider Annexon, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Annexon wasn't on the list.
While Annexon currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
